What Aardvark Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 2 |
| Sells | 2 | 2 |
| Total trades | 2 | 4 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 1,180 |
| Disposed | 0 | 0 |
| Net activity | +0 | +1,180 |
Common stock only — 2 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Sun Nelson | See Remarks | Sep 11 | Disclosed 10b5-1 sale · S | −62,000 | $5.18 | −$321K | 35,475 |
| Sun Nelson | See Remarks | Sep 10 | Disclosed 10b5-1 sale · S | −14,754 | $5.00 | −$73.8K | 97,475 |
| Lee Tien-Li | Chief Executive Officer | Dec 11 | Open-market buy · P | +7,000 | $14.49 | +$101K | 1,551,613 |
| Sun Nelson | Chief Financial Officer | Dec 11 | Open-market buy · P | +3,000 | $14.40 | +$43.2K | 108,484 |
| Lee Tien-Li | Chief Executive Officer | Oct 15 | Exercise / conversion · M | +1,229 | $4.24 | +$5.21K | 1,544,613 |
| Jones Bryan | Chief Operating Officer | Oct 15 | Exercise / conversion · M | +1,250 | $4.24 | +$5.3K | 1,250 |
| Lee Tien-Li | Chief Executive Officer | Sep 15 | Open-market buy · P | +3,500 | $9.94 | +$34.8K | 1,543,384 |
| Lee Tien-Li | Chief Executive Officer | Sep 15 | Open-market buy · P | +6,500 | $9.51 | +$61.8K | 1,539,884 |
| Lee Tien-Li | Chief Executive Officer | Sep 12 | Open-market buy · P | +5,000 | $8.50 | +$42.5K | 1,533,384 |
| Lee Tien-Li | Chief Executive Officer | Sep 11 | Open-market buy · P | +6,000 | $7.82 | +$46.9K | 1,528,384 |
| Lee Tien-Li | Chief Executive Officer | Sep 10 | Open-market buy · P | +9,000 | $7.91 | +$71.2K | 1,522,384 |
| Sun Nelson | Chief Financial Officer | Sep 09 | Open-market buy · P | +6,000 | $8.07 | +$48.4K | 105,484 |
| Lee Tien-Li | Chief Executive Officer | Aug 28 | Exercise / conversion · M | +17,209 | $4.24 | +$73K | 1,513,384 |
| Cormorant Asset Management, Lp | Insider | Feb 14 | Open-market buy · P | +187,500 | $16.00 | +$3M | 987,689 |
| Cormorant Asset Management, Lp | Insider | Feb 14 | Derivative Conversion · C | +800,189 | — | — | 800,189 |
| Chi Jeffrey | Director | Feb 14 | Derivative Conversion · C | +133,364 | — | — | 133,364 |
| Vickers Venture Fund Vi Pte Ltd | 10% owner | Feb 14 | Derivative Conversion · C | +413,491 | — | — | 2,050,902 |
| Vickers Venture Fund Vi Pte Ltd | 10% owner | Feb 14 | Derivative Conversion · C | +1,637,411 | — | — | 1,637,411 |
| Decheng Capital Global Life Sciences Fund IV, L.p. | 10% owner | Feb 14 | Open-market buy · P | +625,000 | $16.00 | +$10M | 958,412 |
| Decheng Capital Global Life Sciences Fund IV, L.p. | 10% owner | Feb 14 | Open-market buy · P | +625,000 | $16.00 | +$10M | 2,958,887 |
Loading...
